Release Date: 2024-06-19

Quality of Life Outcomes After the Management of Metastatic Prostate Cancer

Alpaslan Yuksel (Author), Elbrus Fehruzlu (Author)

Release Date: 2024-06-19

Patients with metastatic prostate cancer (mPCa) often endure significant physical and psychological effects from treatment, impacting relationships, work, and overall quality of life (QoL). Common treatments like surgery, androgen deprivation therapy (ADT), radiotherapy, and chemotherapy each have unique side effects. Post-surgery, patients may face erectile dysfunction, incontinence, and other complications. Radiotherapy can lead to intestinal [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inCurrent Management of Metastatic Prostate Cancer
    First Page161
    Last Page166
    DOIhttps://doi.org/10.69860/nobel.9786053359142.16
    Page Count6
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Patients with metastatic prostate cancer (mPCa) often endure significant physical and psychological effects from treatment, impacting relationships, work, and overall quality of life (QoL). Common treatments like surgery, androgen deprivation therapy (ADT), radiotherapy, and chemotherapy each have unique side effects. Post-surgery, patients may face erectile dysfunction, incontinence, and other complications. Radiotherapy can lead to intestinal toxicity and secondary cancers. ADT frequently results in sexual dysfunction, cognitive decline, and increased risks of fractures and cardiovascular issues. Addressing these side effects and incorporating supportive measures, such as regular physical activity and bone health management, is crucial to enhance the QoL in mPCa patients.

    Alpaslan Yuksel (Author)
    MD, Istanbul Medeniyet University
    https://orcid.org/0000-0003-0076-4812
    3Alpaslan Yuksel graduated from Marmara Universityf Faculty of Medicine. He contributed to many academic publications and served as a faculty member for approximately 9 years. He made academic contributions to academic publications and abstracts of congress regarding Bladder Tumor.

    Elbrus Fehruzlu (Author)
    MD, Istanbul Medeniyet University
    https://orcid.org/0009-0006-7434-1774
    3Elbrus Fehruzlu graduated from Azerbaijan University Faculty of Medicine in 2019. He is currently working as a 3rd year research assistant in Göztepe Medeniyet University Faculty of Medicine, Department of Urology. Urooncology is within his field of interest.

    • Yiannopoulou, K.G., et al. Cognitive and Psychological Impacts of Different Treatment Options for Prostate Cancer: A Critical Analysis. Curr Urol, 2020; 14: 169.

    • Parekh, A., et al. Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology, 2013; 81: 130.

    • Resnick, M.J., et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med, 2013; 368: 436.

    • Donovan, J.L., et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med, 2016; 375: 1425.

    • Wallis, C.J., et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ, 2016; 352: i851.

    • Rodda, S., et al. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys, 2017; 98: 286.

    • Joseph, D., et al. Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial. Int J Radiat Oncol Biol Phys, 2020; 106: 693.

    • Budaus, L., et al. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol, 2012; 61: 112.

    • Walker, L.M., et al. Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Cancer, 2013; 11: 375.

    • Cherrier, M.M., et al. Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psychooncology, 2009; 18: 237.

    • Alibhai, S.M., et al. Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer. Cancer, 2017. 123: 237.

    • Iversen, P., et al. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int, 2001; 87: 47. https://pubmed.ncbi.nlm.nih.gov/11121992

    • Boccardo, F., et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol, 1999; 17: 2027. https://pubmed.ncbi.nlm.nih.gov/10561254

    • Smith, M.R., et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol, 2006; 175: 136. https://pubmed.ncbi.nlm.nih. gov/16406890

    • Braga-Basaria, M., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol, 2006; 24: 3979. https://pubmed. ncbi.nlm.nih.gov/16921050

    • Keating, N.L., et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst, 2010; 102:https://pubmed.ncbi.nlm.nih.gov/19996060

    • Gilbert, S.E., et al. Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer. Br J Cancer, 2016; 114: 401. https://pubmed.ncbi.nlm.nih.gov/26766737

    • Cao, B., et al. Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis. Eur Urol Oncol, 2023; 6: 237. https://pubmed.ncbi.nlm.nih.gov/36682938

    • Wilding, S., et al. Cancer-related symptoms, mental well-being, and psychological distress in men diagnosed with prostate cancer treated with androgen deprivation therapy. Qual Life Res, 2019; 28: 2741. https://pubmed.ncbi.nlm.nih.gov/31115843

    • Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res. 2016 Mar;27(3):367-75.

    • Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011 Feb 20;29(6):726-32

    • Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci L, Plymate SR, Praet SFE et.al. Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open. 2018 May 14;8(5):e022899.

    • Coleman, R., et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol, 2020; 31: 1650.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!